UK Clinical Vaccine Network Conference 2022

Bringing together and showcasing the work of the UK clinical vaccine community, to facilitate co-operation and collaborate on future challenges.

Register now

It is with great excitement that we can announce this year’s Clinical Vaccine Network Conference will be held in person at the Royal College of Physicians, London.

Hosted on the 30th June, this event will cover a wide spectrum of issues in vaccine development, presentations on the latest research, and the future of vaccines.

Whilst this conference will be made available to join virtually we thoroughly recommend attending in person to not miss out on this excellent networking opportunity. There will be an array of UK healthcare professionals, and other relevant decision makers who have a specific interest in vaccine intervention in the patient pathway.

Please share the flyer for the event available here with your colleagues.

If you have any queries, or would like to enquire about sponsorship of this event, please contact:


To view the recordings from the online UK Clinical Vaccine Network Conference held in 2020 please click here

Professor Shiranee Sriskandan

Shiranee Sriskandan is Professor of Infectious Diseases at Imperial College London and a Clinical Infectious Diseases consultant at Hammersmith Hospital which houses one of London’s main adult infectious diseases in-patient units. She leads the Gram Positive Pathogenesis research group at Imperial College within the Department of Infectious Disease, where she is a Head of Section (Adult Infectious Diseases), and MRC Centre for Molecular Bacteriology and Infection.

Her group addresses the mechanisms by which Streptococcus pyogenes causes extreme clinical phenotypes in individuals and populations, examining pathogen molecular microbiology and host immune response, working in close collaboration with colleagues in Public Health England. Recent work focusses on novel approaches to developing vaccines, with colleagues from structural and leukocyte biology, and changes in S. pyogenes that might influence vaccine targets.